0000000000444993
AUTHOR
M Volm
Role of P-Glycoprotein for Resistance of Tumors to Anticancer Drugs: From Bench to Bedside
Success of cancer chemotherapy is limited by simultaneous resistance towards many anticancer drugs making clinical combination therapy protocols less efficient. P-glycoprotein represents an efflux pump of the ABC transporter family, which recognizes and extrudes anticancer drugs of diverse chemical classes and biochemical functions. The P-glycoprotein-mediated profile of cross-resistance has been termed multidrug resistance (MDR). In our investigations, we focused on MDR of in vivo tumor lines maintained in mice. The development of in vivo resistance towards anthracyclines (doxorubicin, daunorubicin) in L1210 and S180 ascites tumor lines was accompanied with decreased uptake and increased e…
Modulation of P-Glycoprotein-Mediated Multidrug Resistance by Synthetic and Phytochemical Small Molecules, Monoclonal Antibodies, and Therapeutic Nucleic Acids
Multidrug resistance of malignant tumors severely hampers their successful treatment frequently leading to fatal consequences for affected patients. During the past three decades, many efforts have been spent to develop strategies to overcome multidrug resistance. Many chemical compounds have been shown to inhibit the drug efflux of the multidrug-resistance-mediating P-glycoprotein. Chemical P-glycoprotein inhibitors are from the classes of calcium channel antagonists, calmodulin inhibitors, cyclosporins, antiarrhythmics, hormones, antimalarials, antibiotics, detergents, beta-blockers, antidepressants, blood pressure lowering indol alkaloids, aerobic glycolysis inhibitors, HIV-protease inhi…